Comparative Study of Oral versus Intravenous Iron Therapy in Patients of Chronic Renal Failure Receiving Recombinant Human Erythropoietin
Keywords:
Chronic Renal Failure (CRF), Total Iron Binding Capacity (TIBC), Human Recombinant Erythropoietin (rHuEPO).Abstract
OBJECTIVE: To evaluate the effects of oral and intravenous Iron on serum ferritin and total Iron binding capacity in patients of chronic renal failure receiving recombinant human erythropoietin.
METHODOLOGY: This prospective comparative interventional study was conducted in the Department of Pharmacology and Therapeutics LUMHS Jamshoro with the collaboration of Urology Department of Liaquat University Hospital (LUH) Jamshoro and Hyderabad, for the duration of 6 months after approval
from research ethics committee of the institute. By using Rao software sampling calculator and after following inclusion and exclusion criteria 80 patients were taken and divided into two groups, Group A (Oral Iron+rHuEPO) & Group B (I/V Iron+rHuEPO). Informed consent was taken from all patients. Serum ferritin & TIBC were done at the beginning and at the end of the six months. Data was analyzed on SPSS version 16.0 (IBM, Incorporation, USA). The continuous variables were analyzed by student’s t-test. The significant p-value was taken at ? 0.05.
RESULTS: Significant statistical improvement was observed in Serum Ferritin and TIBC of both Groups (Group A and Group B). But there is more prominent improvement in serum ferritin and TIBC of Group B (I/V iron + rHuEPO). No adverse effects of iron therapy and erythropoietin therapy were observed in
patients of both groups.
CONCLUSION: The present study concludes that treatment with I/V Iron + Erythropoietin therapy significantly improves Serum Ferritin and TIBC of CRF patients of Group B who received Intravenous Iron Dextran 2ml diluted in 200ml normal saline twice a month + rHuEPO 2000 IU SC twice a week.
Downloads
Published
How to Cite
Issue
Section
License
Submission of a manuscript to the journal implies that all authors have read and agreed to the content of the undertaking form or the Terms and Conditions.
When an article is accepted for publication, the author(s) retain the copyright and are required to grant the publisher the right of first publication and other non-exclusive publishing rights to JLUMHS.
Articles published in the Journal of Liaquat University of Medical & health sciences are open access articles under a Creative Commons Attribution-Noncommercial - Share Alike 4.0 License. This license permits use, distribution and reproduction in any medium; provided the original work is properly cited and initial publication in this journal. This is in accordance with the BOAI definition of open access. In addition to that users are allowed to remix, tweak and build upon the work non-commercially as long as appropriate credit is given and the new creations are licensed under the identical terms. Or, in certain cases it can be stated that all articles and content there in are published under creative commons license unless stated otherwise.
